Benefits
Digestive Comfort
Biombalance is positioned to support day-to-day digestive comfort and reduce occasional bloating and abdominal discomfort. In manufacturer-reported human studies most participants said their digestive discomfort became easier to manage, though independent peer-reviewed confirmation is still limited.
Balanced Gut Microbiota
Grape seed proanthocyanidins act as polyphenol substrates that gut bacteria ferment, which can favor beneficial groups and discourage less desirable ones. In animal models Biombalance helped protect microbial balance during gut stress.
Calms Low-Grade Gut Inflammation
In preclinical colitis models Biombalance reduced markers of inflammation in the gut lining and helped preserve the intestinal barrier, supporting its positioning for maintaining a healthy, resilient gut wall.
Antioxidant Support
Like other grape seed OPC extracts, Biombalance is a strong scavenger of free radicals. This antioxidant activity helps protect cells in the digestive tract from oxidative stress.
Gut-Brain Axis Signaling (Emerging)
Early research reports that Biombalance can influence gut-brain messengers, including GLP-1 and neuropeptide Y expression in the intestine. These findings are preliminary and come mainly from laboratory and animal work, not yet large human trials.
Mechanism of action
B-Type Proanthocyanidin Antioxidant Activity
Biombalance is concentrated in oligomeric procyanidins, which donate electrons to neutralize reactive oxygen species and help regulate oxidative stress in the gut lining.
Microbiota Modulation
Poorly absorbed in the upper gut, grape seed OPCs reach the colon largely intact, where resident bacteria metabolize them. This can shift the microbiome toward a more favorable profile and increase beneficial metabolites.
Anti-Inflammatory Signaling
In preclinical models Biombalance lowered pro-inflammatory mediators and helped maintain tight-junction integrity of the intestinal barrier, supporting a calmer, less permeable gut wall.
Gut-Brain Axis and GLP-1 (Preclinical)
Laboratory and animal studies report that Biombalance increased intestinal expression of GLP-1 and its receptor and of neuropeptide Y. These pathways link gut signaling to appetite and mood, but the impact in humans is not yet established.
Clinical trials
Controlled animal study in a chemically induced mouse colitis model, published in Antioxidants (2025).
Mice with induced colitis.
Biombalance reduced intestinal inflammation, limited microbiota disruption (dysbiosis), and helped protect the gut barrier compared with untreated colitis animals.
Laboratory and cell-based characterization of Biombalance published in Antioxidants (2025).
Bacterial cultures, intestinal cells, and animal tissue.
Biombalance showed antibacterial, antioxidant, and anti-inflammatory activity and increased expression of gut-brain mediators including GLP-1 and neuropeptide Y in a dose-dependent way.
Manufacturer-reported human pilot and randomized, placebo-controlled studies described by Groupe Berkem.
Adults with occasional digestive discomfort.
Over 90 percent of participants reported their gastrointestinal discomfort was easier to manage, and about 72 percent said they no longer had to change their diet to avoid discomfort. Full peer-reviewed publication of these human results is still emerging.